Effect of Intra Operative Intravenous Injection of Heparin on Patency Rate of Radio Cephalic Autogenous Arteriovenous-Fistula in Chronic Renal Failure Patients
Archives of Critical Care Medicine,
Vol. 1 No. 2 (2015),
27 October 2023
Abstract
Background: Currently, there is no standard for the use of systemic heparin during creation of Arteriovenous (AV) fistula to decrease the incidence of postoperative thrombotic complications.
Objectives: The goal of this study was to evaluate the effects of intra-operative IV heparin on patency rate and postoperative bleeding complications in patients undergoing surgery for AV fistula.
Patients and Methods: A prospective, randomized controlled study was performed on 50 patients undergoing AV fistula creation, who were randomly divided in two groups. The control group received no systemic heparin and the heparin group received 5,000 units of intravenous heparin before clamping of theartery.
Results: There was a significant difference in patency rate between the heparin and control groups (96% vs. 72%, P = 0.021), and there were no significant differences in operative time (P = 0.55). Perioperative bleeding was not significantly different between the two groups.
Conclusions: The results suggest that intra operative administration of heparin has statistically significant effects on patency rates yet not on postoperative bleeding complications. Larger trials with longer follow-up durations and assessment of maturation rates are needed to determine this effect on fistula outcome.
- Systemic Heparin
- AV Fistula
- Patency Rate
How to Cite
References
Puskar D, Pasini J, Savic I, Bedalov G, Sonicki Z. Survival of primary arteriovenous fistula in 463 patients on chronic hemodialysis.
Croat Med J. 2002;43(3):306–11.
Brescia MJ, Cimino JE, Appel K, Hurwich BJ. Chronic hemodialysis using venipuncture and a surgically created arteriovenous
fistula. N Engl J Med. 1966;275(20):1089–92.
Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E,
Gillespie B, et al. Vascular access use in Europe and the United
States: results from the DOPPS. Kidney Int. 2002;61(1):305–16.
Quinton W, Dillard D, Scribner BH. Cannulation of blood vessels for prolonged hemodialysis. Trans Am Soc Artif Intern Organs.
;6:104–13.
Bennion RS, Wilson SE. Hemodialysis and vascular access. In:
Moore WS, Barlow L, editors. Vascular surgery: a comprehensive review. 6 ed. Philadelphia: W.B. Sounders; 2001. pp. 626–47.
Harland RC. Placement of permanent vascular access devices:
surgical considerations. Adv Ren Replace Ther. 1994;1(2):99–106.
Wang BR, Rowe VL, Ham SW, Han S, Patel K, Weaver FA, et al. A
prospective clinical evaluation of the effects of intraoperative
systemic anticoagulation in patients undergoing arteriovenous
fistula surgery. Am Surg. 2010;76(10):1112–4.
Bhomi KK, Shrestha S, Bhattachan CL. Role of systemic anticoagulation in patients undergoing vascular access surgery. Nepal
Med Coll J. 2008;10(4):222–4.
National Kidney Foundation III. NKF-K/DOQI Clinical Practice
Guidelines for Vascular Access: update 2000. Am J Kidney Dis.
;37(1 Suppl 1):S137–81.
Kinnaert P, Vereerstraeten P, Toussaint C, Van Geertruyden J. Nine
years' experience with internal arteriovenous fistulas for haemodialysis: a study of some factors influencing the results. Br J Surg.
;64(4):242–6.
Berman SS, Gentile AT. Impact of secondary procedures in autogenous arteriovenous fistula maturation and maintenance. J Vasc
Surg. 2001;34(5):866–71.
Huber TS, Ozaki CK, Flynn TC, Lee WA, Berceli SA, Hirneise CM, et
al. Prospective validation of an algorithm to maximize native arteriovenous fistulae for chronic hemodialysis access. J Vasc Surg.
;36(3):452–9.
Kherlakian GM, Roedersheimer LR, Arbaugh JJ, Newmark KJ,
King LR. Comparison of autogenous fistula versus expanded
polytetrafluoroethylene graft fistula for angioaccess in hemodialysis. Am J Surg. 1986;152(2):238–43.
Silva MJ, Hobson R2, Pappas PJ, Jamil Z, Araki CT, Goldberg MC, et
al. A strategy for increasing use of autogenous hemodialysis access procedures: impact of preoperative noninvasive evaluation.
J Vasc Surg. 1998;27(2):302–7.
Hodges TC, Fillinger MF, Zwolak RM, Walsh DB, Bech F, Cronenwett JL. Longitudinal comparison of dialysis access methods:
risk factors for failure. J Vasc Surg. 1997;26(6):1009–19.
Ascher E, Gade P, Hingorani A, Mazzariol F, Gunduz Y, Fodera M,
et al. Changes in the practice of angioaccess surgery: impact of
dialysis outcome and quality initiative recommendations. J Vasc
Surg. 2000;31(1 Pt 1):84–92.
Rao RK, Azin GD, Hood DB, Rowe VL, Kohl RD, Katz SG, et al. Basilic
vein transposition fistula: a good option for maintaining hemodialysis access site options? J Vasc Surg. 2004;39(5):1043–7.
Yevzlin AS, Conley EL, Sanchez RJ, Young HN, Becker BN. Vascular
access outcomes and medication use: a USRDS study. Semin Dial.
;19(6):535–9.
Flye MW, Mundinger GJ, Schulz SC, Karsh J, Van Kammen DP. Successful creation of arteriovenous fistulas in nonuremic patients
with heparin and aspirin therapy. Am J Surg. 1981;142(6):759–63.
D'Ayala M, Smith RM, Martone C, Briggs W, Deitch JS, Wise L. The
effect of systemic anticoagulation in patients undergoing angioaccess surgery. Ann Vasc Surg. 2008;22(1):11–5.
Erkut B, Unlu Y, Ceviz M, Becit N, Ates A, Colak A, et al. Primary arteriovenous fistulas in the forearm for hemodialysis: effect of miscellaneous factors in fistula patency. Ren Fail. 2006;28(4):275–81.
Hakaim AG, Nalbandian M, Scott T. Superior maturation and
patency of primary brachiocephalic and transposed basilic
vein arteriovenous fistulae in patients with diabetes. J Vasc Surg.
;27(1):154–7.
Palder SB, Kirkman RL, Whittemore AD, Hakim RM, Lazarus JM,
Tilney NL. Vascular access for hemodialysis. Patency rates and
results of revision. Ann Surg. 1985;202(2):235–9.
Sharathkumar A, Hirschl R, Pipe S, Crandell C, Adams B, Lin JJ. Primary thromboprophylaxis with heparins for arteriovenous fistula failure in pediatric patients. J Vasc Access. 2007;8(4):235–4
- Abstract Viewed: 250 times
- PDF Downloaded: 3 times